Clinical trials: Oral Anticoagulant
Anticoagulant Antagonists, Vitamin K and Other Coagulants Causing Adverse Effects in Therapeutic Use, Atrial Fibrillation
Evaluation of Oral Anticoagulation With Vitamin K Antagonists - The thrombEVAL Study Programme
Since decades, oral anticoagulation (OAC) with vitamin K antagonists (VKA) is an established therapy for both prevention and treatment of thromboembolism in daily clinical routine.
- Conditions
- Anticoagulant Antagonists, Vitamin K and Other Coagulants Causing Adverse Effects in Therapeutic Use, Atrial Fibrillation, Venous Thromboembolism
- Trial name
- thrombEVAL (NCT01809015)
- Where
- Germany
- Volunteers
- 2,318 people
- Sponsor
- Johannes Gutenberg University Mainz
Atrial Fibrillation
Decentralized Trial in Atrial Fibrillation Patients
The purpose of this study is to validate an approach to decentralize, or virtualize, the clinical trial experience for enrolled subjects, through the coordinated use of multiple digital health and telehealth technologies.
- Trial name
- DeTAP (NCT04471623)
- Testing
- Use of DeTAP App and Home Devices
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- Stanford University
Anticoagulant Therapy
Pharmacokinetics and Point of Care Testing of Direct Oral Anticoagulants Subjects
DOACs are increasingly used since 8 years. Standard coagulation tests (Prothrombin time [PT] and activated partial thromboplastin time [aPTT]) from plasma samples show a high variation.
- Trial name
- PHAPOCU (NCT05491460)
- Testing
- Apixaban 5 MG Tab, Dabigatran 150 MG Tab, Edoxaban 60Mg Tab
- Where
- Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Doasense GmbH
Venous Thromboembolism
Predicting Bleeding Risk on Anticoagulant Therapy for Venous Thromboembolism
The main objective of the study is to develop or validate a clinical prediction rule for major bleeding in patients on oral anticoagulant therapy who have been safely anticoagulated without bleeding or venous thromboembolism…
- Trial name
- NCT00788736
- Where
- 12 sites in United States, Canada and 1 more
- Volunteers
- 2,537 people
- Sponsor
- Ottawa Hospital Research Institute
Craniocerebral Trauma, Cerebral Hemorrhage
Mild Head Injury, Antiplatelets, and Anticoagulants
Approximately 20% of patients with mild head injury presenting to the Emergency Department (ED) is taking antiplatelet agents and 10% is taking oral anticoagulants.
- Trial name
- NCT04741334
- Testing
- direct anticoagulant, antiplatelet drugs, Dicumarols
- Where
- Italy
- Volunteers
- 2,127 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Uterine Hemorrhage
A Study of Severe Uterine Bleeding Following Exposure to Direct Oral Anticoagulants
The purpose of this study is assess the: (a) incidence of severe uterine bleeding (SUB) following exposure to individual direct oral anticoagulant (DOACs) (rivaroxaban, apixaban, dabigatran) and warfarin, (b) individual DOACs…
- Trial name
- NCT04394234
- Testing
- Direct oral anticoagulant (DOACs), Warfarin
- Where
- United States
- Volunteers
- 961,985 people
- Sponsor
- Janssen Research & Development, LLC
Anticoagulants; Increased
Restart TICrH Alpha Pilot Protocol, Restarting DOACs After Traumatic Intracranial Hemorrhage
Randomized pilot trial of restarting DOACs at 1 week versus 4 weeks after traumatic intracranial hemorrhage
- Trial name
- NCT04891861
- Testing
- Apixaban
- Volunteers
- 100 people
- Sponsor
- University of Texas at Austin
Portal Vein Thrombosis, Anticoagulant Therapy
Direct Oral Novel Anticoagulants for Patients With High-risk Gastroesophageal Variceal Bleeding and Portal Vein Thrombosis
This study aims to explore the safety and efficacy of oral administration of a novel anticoagulant (rivaroxaban) in patients with cirrhosis accompanied by high-risk esophagogastric variceal bleeding and portal vein thrombosis…
- Conditions
- Portal Vein Thrombosis, Anticoagulant Therapy, Variceal Bleeding
- Trial name
- NCT07602062
- Testing
- Rivaroxaban
- Where
- China
- Volunteers
- 175 people
- Sponsor
- Shanghai Zhongshan Hospital
Thromboembolism
Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE)
The general aim of this study is to determine the comparative safety and efficacy of dabigatran etexilate 150 mg bid administered orally and warfarin Pro re nata (As needed/PRN) to maintain an International Normalised Ratio (INR)…
- Trial name
- RE-COVER II (NCT00680186)
- Testing
- Warfarin, Dabigatran etexilate
- Where
- 220 sites in United States, Australia and 29 more
- Volunteers
- 2,589 people
- Sponsor
- Boehringer Ingelheim
Anticoagulated Patients
Short-term Interruption Versus Continuous Anticoagulation in Colorectal Polypectomy
This study is designed to find out if it is safe to keep taking blood-thinning medicine during the removal of polyps from the colon or rectum.
- Trial name
- POLYPHEM (NCT07185295)
- Testing
- To maintain anticoagulant therapy during the polypectomy of colorectal lesions
- Where
- 10 sites in Spain
- Volunteers
- 481 people
- Sponsor
- Outcomes'10
Non-valvular Atrial Fibrillation
Safety and Effectiveness of Oral Anticoagulants in Patients With Non-valvular Atrial Fibrillation
An anticoagulation therapy is a critical treatment to prevent thromboembolism in non-valvular AF (NVAF) patients. Warfarin, a vitamin K antagonist, is the first oral anticoagulant approved for the treatment for prevention of…
- Trial name
- CER3 (NCT03570047)
- Where
- Japan
- Volunteers
- 73,989 people
- Sponsor
- Pfizer
Nonvalvular Atrial Fibrillation
The Adherence to Oral Anticoagulant in Chinese Patients With NVAF
Investigate the compliance of oral anticoagulants in Chinese NVAF patients and find out the causes, so as to provide basis for formulating effective measures to improve the compliance of oral anticoagulants.
- Trial name
- NVAF (NCT04942873)
- Testing
- adherence
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Upper Gastrointestinal Bleeding
Non-warfarin Oral AntiCoagulant Resumption After Gastrointestinal Bleeding in Atrial Fibrillation Patients
Current clinical society guidelines and statements are non-specific and relatively open-ended regarding the optimal timing to restart non-warfarin oral anticoagulant (NOAC) after gastrointestinal bleeding (GIB) in patients with…
- Trial name
- NOAC-GAP (NCT03785080)
- Testing
- restart NOAC very early, restart NOAC early
- Where
- 3 sites in Australia, Hong Kong and 1 more
- Volunteers
- 552 people
- Sponsor
- Chinese University of Hong Kong
Anticoagulants, Quality of Life
Quality of Life and Efficacy Evaluation of Patient Self-monitoring Their Oral Anticoagulation Therapy
The purpose of this study is to determine whether self-management of oral anticoagulation therapy with warfarin has an effect on patient's quality of life following a specific training program led by pharmacists.
- Conditions
- Anticoagulants, Quality of Life, Drug Monitoring, Pharmacy
- Trial name
- ESCAPE (NCT01033279)
- Testing
- Self-monitoring and adjustment of oral anticoagulation
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Montreal Heart Institute
Blood Coagulation
Safety of Oral Anticoagulants Registry
The goal of SOAR is to characterize the clinical and economic impact of clinicians' responses to major bleeding complications and pre-procedural concerns for bleeding risk in patients treated with oral anticoagulants (warfarin…
- Trial name
- SOAR (NCT02745054)
- Testing
- mgt of bleeding concerns/complications of oral anticoagulants
- Where
- 9 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Hospital Quality Foundation
Percutaneous Coronary Intervention (PCI), Atrial Fibrillation (AF)
Monotherapy With P2Y12 Inhibitors in Patients With Atrial fIbrillation Undergoing Supraflex Stent Implantation
Patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation require treatment with different antithrombotic drugs.
- Conditions
- Percutaneous Coronary Intervention (PCI), Atrial Fibrillation (AF), Oral Anticoagulation, P2Y12 Inhibitor
- Trial name
- MATRIX-2 (NCT05955365)
- Testing
- P2Y12 inhibitor, Aspirin, DOAC
- Where
- 15 sites in Belgium, France and 7 more
- Volunteers
- 3,010 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Acquired Coagulation Factor Deficiency
Prothrombin Complex Concentrate for Anticoagulant Reversal
Patients on oral anticoagulants need rapid reversal of the anticoagulant effect in case of acute bleeding or emergency surgery. Prothrombin Complex Concentrates are known to provide a fast reversal of the anticoagulant effect…
- Trial name
- NCT00168077
- Testing
- Prothrombin Complex Concentrate
- Where
- 15 sites in Austria, Germany and 6 more
- Volunteers
- 40 people
- Sponsor
- CSL Behring
Correction of Cancer-related Coagulopathy With Novel Oral Anticoagulant (Edoxaban)
Edoxaban for the Treatment of Coagulopathy in Patients With Active Cancer and Acute Ischemic Stroke: a Pilot Study. (ENCHASE Study)
Purpose: Cancer-related hypercoagulability plays an important role in the development of cancer-related stroke. With rapidly aging population and increasing cancer prevalence, cancer related stroke has become an important stroke…
- Trial name
- ENCHASE (NCT03570281)
- Testing
- Edoxaban, Enoxaparin
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Samsung Medical Center
DOAC Eligible Subjects
Direct Oral Anticoagulant Assay Detection & Classification Study for the TEG 6S System
Observational trial to evaluate the effectiveness of the TEG6s DOAC cartridge to detect and classify the presence of DOAC drugs in a subject.
- Trial name
- NCT02798328
- Testing
- TEG6s DOAC Cartridge
- Where
- 4 sites in United States
- Volunteers
- 385 people, healthy volunteers welcome
- Sponsor
- Haemonetics Corporation
Heavy Menstrual Bleeding
Prospective Comparison of Incidence of Heavy Menstrual Bleeding in Women Treated With Direct Oral Anticoagulants
Prospective comparison of the incidence of heavy menstrual bleeding (HMB) in women of reproductive age treated with direct oral anticoagulants (DOACs)
- Trial name
- NCT04477837
- Testing
- Apixaban 5 MG, Rivaroxaban 20 MG, Edoxaban 60 MG
- Where
- Germany
- Volunteers
- 84 people
- Sponsor
- Cardioangiologisches Centrum Bethanien